Matthias, Christoph

[["dc.bibliographiccitation.firstpage","662"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Otology Rhinology & Laryngology"],["dc.bibliographiccitation.lastpage","669"],["dc.bibliographiccitation.volume","118"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Blomeyer, Barbara D."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T11:24:31Z"],["dc.date.available","2018-11-07T11:24:31Z"],["dc.date.issued","2009"],["dc.description.abstract","Objectives: Treatment methods for patients with cervical cancer of an unknown primary site (CUP) are still under discussion. The purpose of this retrospective study was to analyze the oncological follow-up of 58 patients treated for cervical CUP. Methods: From 1986 to 2006, 58 patients with cervical CUP were treated at the authors' institution. Treatment consisted of neck dissection alone in 8, irradiation or chemoradiation in 5, combined surgery and radiotherapy in 28, and surgery and radiochemotherapy in 17. Results: The 3-year and 5-year overall survival rates for all patients were 52.9% and 40.9%, respectively. The 3-year and 5-year disease-specific Survival rates were 50.9% and 39.7%, respectively. The 3-year and 5-year neck control rates were 73.7% and 67.3%, respectively. Neck dissection followed by radiochemotherapy was associated with the best 3-year and 5-year locoregional control rates. Extracapsular extension was a predictor of survival, but not of neck control. Distant metastases developed in about one third of all patients and were the most frequent cause of tumor-related death in cases of advanced neck disease. Conclusions: Despite the fact that regional control can be achieved in many cases, survival rates may be limited by distant metastasis, especially in patients with advanced neck disease."],["dc.identifier.isi","000270190000010"],["dc.identifier.pmid","19810608"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56424"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Annals Publ Co"],["dc.relation.issn","0003-4894"],["dc.title","Impact of Distant Metastasis in Patients With Cervical Lymph Node Metastases From Cancer of an Unknown Primary Site"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","859"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK"],["dc.bibliographiccitation.lastpage","866"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kron, Martina"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Steiner, Wolfgang"],["dc.date.accessioned","2018-11-07T09:39:38Z"],["dc.date.available","2018-11-07T09:39:38Z"],["dc.date.issued","2014"],["dc.description.abstract","BackgroundThe purpose of this study was to evaluate oncological and functional results of transoral laser microsurgery (TLM) in patients with T2 and T3 glottic laryngeal squamous cell carcinoma (SCC). MethodsA retrospective chart analysis was carried out. Cases were classified into categories pT2a, pT2b, and pT3. Treatment was exclusively TLMselective neck dissection and adjuvant (chemo)radiotherapy. ResultsThree hundred ninety-one patients were treated by TLM; 142 cases were category pT2a, 127 were pT2b, and 122 were pT3. Median follow-up was 71 months. Five-year overall, recurrence-free, and disease specific survival rates were 72.2%, 76.4%, and 93.2% for pT2a tumors, 64.9%, 57.3%, and 83.9% for pT2b tumors, and 58.6%, 57.8%, and 84.1% for pT3 tumors, respectively. Larynx preservation was achieved in 93% (pT2a) and 83% (pT2b and pT3). ConclusionResults are comparable to open partial or total laryngectomy and superior to primary (chemo)radiotherapy. TLM results in a lower morbidity and superior function compared to standard treatment. (c) 2013 Wiley Periodicals, Inc. Head Neck 36: 859-866, 2014"],["dc.identifier.doi","10.1002/hed.23389"],["dc.identifier.isi","000336493200019"],["dc.identifier.pmid","23720321"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33329"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0347"],["dc.relation.issn","1043-3074"],["dc.title","Transoral laser microsurgery in treatment of pT2 and pT3 glottic laryngeal squamous cell carcinoma - results of 391 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","531"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","The Laryngoscope"],["dc.bibliographiccitation.lastpage","537"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Koehler, Sabrina"],["dc.contributor.author","Meyer, Alexander C."],["dc.contributor.author","Blum, Jenny"],["dc.contributor.author","Strenzke, Nicola"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:44:44Z"],["dc.date.available","2018-11-07T09:44:44Z"],["dc.date.issued","2014"],["dc.description.abstract","Objectives/HypothesisTo review the results of obliteration of a preexisting mastoid cavity with abdominal fat and Vibrant Soundbridge implantation in patients with mixed hearing loss (MHL) and to compare the data with results of Vibrant Soundbridge implantation in patients with MHL without mastoid cavity and with pure sensorineural hearing loss (SNHL). Study DesignRetrospective chart analysis of 10 patients (10 ears) with MHL and preexisting mastoid cavity, 18 patients (19 ears) with MHL alone and nine patients (10 ears) with SNHL treated in one tertiary referral center. MethodsVibrant Soundbridge implantation and obliteration in case a mastoid cavity existed previously. Pure tone audiometry (average air-bone gap, average functional gain), speech audiometry (Freiburg Monosyllabic Test) and complication rate were main outcome measures. ResultsPostoperative average air-bone gap was -15.121.2 dB in patients with MHL with mastoid cavity obliteration, -7.211.4 dB in patients with MHL without mastoid cavity, and -5.7 +/- 11.2 dB in patients with SNHL. Average functional gain was 40.0 +/- 23.5 dB, 39.7 +/- 12.1 dB, and 9.5 +/- 10.6 dB. Postoperative speech discrimination rate was 77.9 +/- 20.8%, 83.3 +/- 13.6%, and 83.6 +/- 6.3%. No severe intraoperative or postoperative complications were noted. ConclusionsMastoid cavity obliteration during Vibrant Soundbridge implantation in patients with MHL and preexisting mastoid cavity is a safe procedure. The audiometric results are satisfying and comparable to those of other patient groups implanted with the same device. Level of Evidence4. Laryngoscope, 124:531-537, 2014"],["dc.description.sponsorship","MED-EL, Innsbruck, Austria"],["dc.identifier.doi","10.1002/lary.24180"],["dc.identifier.isi","000329929900041"],["dc.identifier.pmid","23918587"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34461"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1531-4995"],["dc.relation.issn","0023-852X"],["dc.title","Mastoid Cavity Obliteration and Vibrant Soundbridge Implantation for Patients With Mixed Hearing Loss"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","864"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiology"],["dc.bibliographiccitation.lastpage","871"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Daldrup, Benjamin"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:58:48Z"],["dc.date.available","2018-11-07T08:58:48Z"],["dc.date.issued","2011"],["dc.description.abstract","Purpose: To test for an association between high-grade acute organ toxicity during adjuvant radiation and chemotherapy and treatment outcome in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Materials and Methods: Institutional review board approval was obtained for this retrospective study. From September 1994 to October 2008, 294 HNSCC patients were treated with adjuvant radiation and chemotherapy at the authors' department. They received normofractionated (2 Gy per fraction) irradiation to include associated nodal drainage sites, for a cumulative dose of 60-64 Gy. From January 2002 to December 2009, 91 patients received additional concomitant cisplatin-based chemotherapy. Toxicity during treatment was monitored weekly according to the common toxicity criteria (CTC); any CTC toxicity grade 3 or higher, including mucositis, dysphagia, or skin reaction, was considered high-grade acute organ toxicity. The influence of possible prognostic factors on overall survival and locoregional control was studied by means of uni- and multivariate Cox regression. Results: A statistically significant association was found between high-grade acute organ toxicity and both overall survival and locoregional control. Patients with CTC grade 3 or greater acute organ toxicity had a 5-year overall survival and locoregional control rate of 90% and 97%, respectively, as compared with 24% and 74%, respectively, in patients without such toxicity (P < .01). Multivariate analyses revealed that this association was independent from other factors that may influence treatment toxicity, especially concomitant chemotherapy and/or radiation therapy. Conclusion: The data suggest that normal tissue and tumor tissue may behave similarly with respect to treatment response, as high-grade acute organ toxicity during radiation and chemotherapy was associated with better outcomes in the patient population; therefore, the hypothesis should be further analyzed on the biomolecular and clinical level and with other tumor entities in prospective clinical trials. (C)RSNA, 2011"],["dc.identifier.doi","10.1148/radiol.10100705"],["dc.identifier.isi","000287573100023"],["dc.identifier.pmid","21339350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23729"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiological Soc North America"],["dc.relation.issn","0033-8419"],["dc.title","High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Adjuvant Radiation and Chemotherapy for Locally Advanced Head and Neck Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","246"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","American Journal of Otolaryngology"],["dc.bibliographiccitation.lastpage","250"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:43:07Z"],["dc.date.available","2018-11-07T09:43:07Z"],["dc.date.issued","2014"],["dc.description.abstract","After laryngectomy or lateral pharyngotomy for treatment of laryngeal or hypopharyngeal cancer the occurrence of a pharyngo-cutaneous fistula is a challenging complication. Especially after previous radiotherapy and expanded surgical resections of mucosa the management is demanding. Besides the prolonged hospital stay, increased treatment costs and reduced quality of life, a delayed adjuvant treatment follows the development of a fistula. Treatment strategies range from conservative procedures comprising parenteral nutrition, antibiotics and local wound care to primary surgical closure or reconstructive tissue transfer. We report three cases of using the fibrin/thrombin-coated collagen patch TachoSil (R) as a solitary or adjuvant strategy in surgical treatment. In one patient primary closure of the fistula was achieved by transoral application of the collagen patch. In the other cases a not tension free primary suture was strengthened by the adjuvant use of TachoSil (R). The healing process was rapid and straightforward in all patients. The use of TachoSil (R) may be indicated in between conservative treatment strategies and reconstructive surgery. After occurrence of a fistula the healing process is intended to be accelerated by primary closure with TachoSil (R) or by sealing of a primary suture. (C) 2014 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.amjoto.2013.11.005"],["dc.identifier.isi","000333541800031"],["dc.identifier.pmid","24315631"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34107"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co-elsevier Inc"],["dc.relation.issn","1532-818X"],["dc.relation.issn","0196-0709"],["dc.title","Coated collagen patches for closure of pharyngo-cutaneous fistulas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Steiner, Wolfgang"],["dc.contributor.author","Matthias, Christoph"],["dc.date.accessioned","2018-11-07T11:23:46Z"],["dc.date.available","2018-11-07T11:23:46Z"],["dc.date.issued","2009"],["dc.format.extent","633"],["dc.identifier.doi","10.1016/j.ijrobp.2009.05.062"],["dc.identifier.isi","000269941600047"],["dc.identifier.pmid","19735892"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56260"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0360-3016"],["dc.title","LARYNX PRESERVATION CLINICAL TRIAL DESIGN: KEY ISSUES AND RECOMMENDATIONS-A CONSENSUS PANEL SUMMARY: IN REGARD TO LEFEBVRE ET AL., FOR THE LARYNX PRESERVATION CONSENSUS PANEL (INT J RADIAT ONCOL BIOL PHYS 2009;73:1293-1303)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","452"],["dc.bibliographiccitation.issue","5-6"],["dc.bibliographiccitation.journal","CANCER DETECTION AND PREVENTION"],["dc.bibliographiccitation.lastpage","457"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Baumeister, Philipp"],["dc.contributor.author","Korn, G."],["dc.contributor.author","Berghaus, Alexander"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Harreus, Ulrich"],["dc.date.accessioned","2018-11-07T08:33:59Z"],["dc.date.available","2018-11-07T08:33:59Z"],["dc.date.issued","2009"],["dc.description.abstract","Introduction: Recent research indicates a close connection of inflammation and cancer as presumed by Virchow in 1893. The growing understanding of cellular signalling and regulatory pathways reveals multiple links between inflammation and cancer. This study was designed to evaluate the influence of the anti-inflammatory drug dexamethasone and the antioxidant alpha-tocopherol on oxidative induced DNA damage, a major factor in the development of malignancies. Material and methods: Miniorgan cultures (MOC) of fresh biopsied human nasal mucosa were used to keep cells in their microenvironment and thus to mimic in vivo conditions. MOC were pretreated with dexamethasone and alpha-tocopherol in different concentrations on 1 or on 5 days before oxidative DNA damage was introduced by hydrogen peroxide. The effect of these substances on DNA damage was evaluated using the alkaline single cell microgel electrophoresis (Comet Assay). Results: Dexamethasone induced slight, but considerable DNA fragmentation by itself. It effectively protected cells from hydrogen peroxide induced DNA damage, leading to a maximum decrease of about 45% when preincubated on 5 days at 20 mu M. alpha-Tocopherol most effectively reduced oxidative DNA fragmentation by about 38% when MOC were pretreated 5 days at 20 mu M. Discussion: Our experimental data clearly shows the DNA protective action of dexamethasone and alpha-tocopherol with regard to oxidatively induced DNA damage, a major pathogenetic factor that inflammation and cancer have in common. (C) 2008 Elsevier Ltd. All fights reserved."],["dc.identifier.doi","10.1016/j.cdp.2008.10.002"],["dc.identifier.isi","000267313700014"],["dc.identifier.pmid","19070971"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17716"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","0361-090X"],["dc.title","Chemopreventive action of dexamethasone and alpha-tocopherol in oxidative stressed cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1589"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","1598"],["dc.bibliographiccitation.volume","273"],["dc.contributor.author","Kuenzel, Julian"],["dc.contributor.author","Hainz, Michael"],["dc.contributor.author","Ziebart, Thomas"],["dc.contributor.author","Pitz, Susanne"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Strieth, Sebastian"],["dc.contributor.author","Matthias, Christoph"],["dc.date.accessioned","2018-11-07T10:13:56Z"],["dc.date.available","2018-11-07T10:13:56Z"],["dc.date.issued","2016"],["dc.description.abstract","The objective of this study is to analyze the outcome of treatment for solitary fibrous tumors (SFTs) in the head and neck area. SFTs present as slow-growing masses, often with local compressive symptoms that are difficult to distinguish from other soft-tissue tumors. SFTs are commonly treated using local excision without adjuvant therapy. To date, only heterogeneous small series have been published, documenting the treatment results and outcome with these tumors. Retrospective study of patients with histopathologically confirmed SFT treated at two tertiary referral hospitals between 2004 and 2014. Eight men and four women with histologically confirmed SFT were identified in the records. Their age range was 37-82 years (mean 57.8 years). The mean follow-up period for eight patients was 6.75 years (range 1-24 years). Four patients were lost to follow-up. Sublocalizations were neck (n = 3), orbit (n = 2), paranasal sinus (n = 2), cheek (n = 2), hard palate (n = 1), parotid gland (n = 1), and tongue (n = 1). The first-line treatment for all of the tumors identified was surgical excision. In four cases, the surgical margins were narrow or unclear due to piecemeal resection in the paranasal sinus and orbit (n = 3) or a tumor location deep in the parapharyngeal space (n = 1). Recurrences developed in two of these cases (in the orbit and parapharyngeal space), and the other two patients were lost to follow-up. Radiotherapy and chemotherapy were not administered as first-line treatments. Overall, the local recurrence rate (n = 2/8) was 25 %. The disease-specific survival rate was 100 %. These results are consistent with the literature data and show that safe surgical excision, without opening of the tumor capsule, reduces the risk of local recurrence and leads to a favorable outcome. Tumors in the head and neck often represent a surgical challenge, and wide surgical margins are rarely possible due to the complex three-dimensional anatomic compartments in the region. Head and neck surgeons should therefore be aware that there is an increased risk of recurrence in these patients; tightly scheduled follow-up visits are mandatory for at least 10 years, if not longer. Radiotherapy only appears to be an option in patients with unresectable tumors or when wide surgical excision would cause severe functional morbidity."],["dc.identifier.doi","10.1007/s00405-015-3670-1"],["dc.identifier.isi","000375607700033"],["dc.identifier.pmid","26026772"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40523"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1434-4726"],["dc.relation.issn","0937-4477"],["dc.title","Head and neck solitary fibrous tumors: a rare and challenging entity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","889"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK"],["dc.bibliographiccitation.lastpage","895"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Steiner, Wolfgang"],["dc.date.accessioned","2018-11-07T09:56:40Z"],["dc.date.available","2018-11-07T09:56:40Z"],["dc.date.issued","2015"],["dc.description.abstract","BackgroundVarious therapeutic options exist for treatment of T1a glottic squamous cell cancer (SCC). Radiotherapy (RT) has been favored over surgical excision. This has been challenged by transoral laser microsurgery (TLM) showing low morbidity and good functional results. MethodsA retrospective chart review was carried out. Patients with untreated T1a glottic SCC were included in the study. Endpoints were locoregional control, overall survival, disease-specific survival, and absolute rate of larynx preservation. ResultsFour hundred four patients were included in this study. Five-year Kaplan-Meier estimates were: local control 86.8%, overall survival 87.8%, disease-specific survival 98.0%, recurrence-free survival 76.1%, and larynx preservation 97.3%. The complication rate was 1%; the majority of patients had either normal or mildly dysphonic voices. ConclusionLow complication rates, excellent functional outcome, and high rates of organ preservation favor TLM. In agreement with the literature, TLM should be the treatment of choice for patients presenting with T1a glottic SCC. (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 889-895, 2015"],["dc.identifier.doi","10.1002/hed.23688"],["dc.identifier.isi","000355012000021"],["dc.identifier.pmid","24623709"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37008"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0347"],["dc.relation.issn","1043-3074"],["dc.title","Transoral laser microsurgery for T1a glottic cancer: Review of 404 cases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","230"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Journal of Cancer Prevention"],["dc.bibliographiccitation.lastpage","235"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Baumeister, Philipp"],["dc.contributor.author","Reiter, Maximilian"],["dc.contributor.author","Kleinsasser, Norbert"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Harreus, Ulrich"],["dc.date.accessioned","2018-11-07T08:29:07Z"],["dc.date.available","2018-11-07T08:29:07Z"],["dc.date.issued","2009"],["dc.description.abstract","Although epidemiological studies indicate cancer preventive effects of diets rich in fruit and vegetables, large clinical intervention studies conducted to evaluate dietary supplementation with micronutrients, mostly vitamins, showed disappointing results in large parts. In contrast there is encouraging epidemiologic data indicating great chemopreventive potential of a large group of phytochemicals, namely polyphenols. This study shows the DNA protective effect epigallocatechin-3-gallate, a tea catechin, and one of the best-studied substances within this group, on carcinogen-induced DNA fragmentation in upper aerodigestive tract cells. Cell cultures from fresh oropharyngeal mucosa biopsies were preincubated with epigallocatechin-3-gallate in different concentrations before DNA damage was introduced with the metabolically activated carcinogen benzo[a]pyrene-7,8-dihydrodiol-9, 10-epoxide or cigarette smoke condensate. Effects on resulting DNA fragmentation were measured using the alkaline single-cell microgel electrophoresis (comet assay). Epigallocatechin-3-gallate significantly reduced benzo[a] pyrene-7,8-dihydrodiol-9,10-epoxide-induced DNA damage by up to 51% (P<0.001). Fragmentation induced by cigarette smoke condensate could be lowered by 47% (P<0.001). Data suggest a cancer preventive potential of epigallocatechin-3-gallate as demonstrated on a subcellular level. An additional mechanism of tea catechin action is revealed by using a primary mucosa culture model. European Journal of Cancer Prevention 18:230-235 (C) 2009 Wolters Kluwer Health "],["dc.identifier.doi","10.1097/CEJ.0b013e32831bc3a0"],["dc.identifier.isi","000265369400011"],["dc.identifier.pmid","19491610"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16574"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0959-8278"],["dc.title","Epigallocatechin-3-gallate reduces DNA damage induced by benzo[a]pyrene diol epoxide and cigarette smoke condensate in human mucosa tissue cultures"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]